

ASX RELEASE

Volpara December Newsletter

Wellington, NZ, 21 December 2017: Volpara Health Technologies ("Volpara"; ASX: VHT), a digital health company focused on early detection of breast cancer by improving quality of screening, is pleased to provide investors with its December Investor Newsletter.

The eNewsletter outlines the Company's recent activities, upcoming events and news:

- FDA's prioritising of mammography quality standards for 2018
- Record leads and a first peek at new products at RSNA 2017
- Year-in-review video interview with Dr Ralph Highnam, CEO
- Signing of Memorial Sloan Kettering Cancer Center
- Regulatory approval in Japan for the full suite of VolparaEnterprise™ products
- A customer success story
- Blog introducing Dr Monica Saini, Volpara's Consultant Radiologist
- Recent research on compression in mammography and breast density changes after oophorectomy
- Recent Volpara and breast density media coverage
- Upcoming events

The Investor Newsletter can be viewed here: <http://bit.ly/2kRo7Bn>

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, and based in Wellington, New Zealand, VHT facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on automated, objective measurements of breast density.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722